Best Agrolife (539660) Q4 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 25/26 earnings summary
28 May, 2026Executive summary
FY26 was challenging due to adverse weather, uneven rainfall, high trade inventory, and raw material price spikes from the Gulf conflict, impacting sales and profitability.
Focus remained on strengthening fundamentals, operational discipline, and long-term business sustainability, including OPEX reduction by 15% YoY and working capital optimization.
Strategic emphasis on expanding patented and specialty product portfolios, with three new patented formulations launched and seven new patents granted, including innovations in Nano Urea and combination products.
International expansion continued with registrations in Mexico, Sri Lanka, Thailand, and Vietnam, and a subsidiary in Brazil in progress.
Operational initiatives included inventory reduction, OPEX reduction, and improved cash flow.
Financial highlights
FY26 consolidated revenue from operations was ₹1,257 crore, down 31% year-over-year from ₹1,814 crore.
Gross margin for FY26 was ₹380 crore (30%), compared to ₹531 crore (29%) in FY25; Q4 FY26 gross margin was ₹35 crore (23%).
EBITDA for FY26 was ₹100 crore (8% margin), down from ₹200 crore (11%) in FY25; Q4 FY26 EBITDA was negative at ₹-27 crore.
Profit after tax for FY26 was ₹9 crore (1% margin), compared to ₹70 crore (4%) in FY25; Q4 FY26 PAT loss was ₹37 crore.
Diluted EPS for FY26 was ₹0.25, down from ₹1.97 in FY25.
Outlook and guidance
Four new patented products are planned for launch in FY27 to drive future growth.
Price increases implemented in April and May 2026 are expected to improve profitability going forward.
Deferred sales of ₹50–70 crore in March are expected to boost Q1 FY27 results.
Focus on product mix improvement, inventory alignment, and increased contribution from differentiated products to support gradual recovery.
Latest events from Best Agrolife
- Branded sales and margins surged in Q2 FY25, with strong cash flow and new patented launches ahead.539660
Q2 24/259 Jul 2026 - Q4 FY25 delivered sharp loss reduction, 103% revenue growth, and margin gains, with new launches ahead.539660
Q4 24/259 Jul 2026 - Q1 saw lower profits and revenue, but branded sales and new launches support a positive outlook.539660
Q1 24/258 Jul 2026 - Q3 FY25 revenue and profit declined amid weak demand, price pressure, and tax probe uncertainty.539660
Q3 24/258 Jul 2026 - Revenue fell 26% YoY in Q3 FY26, but margins improved and new patented products gained share.539660
Q3 25/2616 Apr 2026 - Margins improved and profits held steady despite a 27% YoY revenue drop.539660
Q1 25/2623 Nov 2025 - Q2 FY26 revenue dropped 30.8% YoY, but cost controls and patented products improved resilience.539660
Q2 25/2614 Nov 2025